[CSCO大家访谈录]如何成功发表SCI?《外科肿瘤学年鉴》主编Charles Balch亲自支招

作者:肿瘤瞭望   日期:2017/10/9 12:04:40  浏览量:26029

肿瘤瞭望版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

中国临床肿瘤学会(CSCO)学术年会从2015年开始设立主席研讨会(Presidential Symposium)专场,2017 CSCO年会主席研讨会主要关注了“如何更好地反映临床研究”以及“如何做好真实世界的研究”等内容。

  编者按:中国临床肿瘤学会(CSCO)学术年会从2015年开始设立主席研讨会(Presidential Symposium)专场,2017 CSCO年会主席研讨会主要关注了“如何更好地反映临床研究”以及“如何做好真实世界的研究”等内容。该专场邀请了《柳叶刀·肿瘤学》(The Lancet Oncology)杂志主编David Collingridge博士以及《外科肿瘤学年鉴》(Annals of Surgical Oncology)主编、美国MD安德森癌症中心Charles Balch教授,从学术期刊编辑角度阐述一项“好研究”的要素。
 
  Charles Balch教授在本次年会上获得「荣誉外籍顾问奖」,获奖理由是:作为杰出的肿瘤外科学家及研究者,他为中国临床肿瘤学会搭建起一座通向世界的桥梁。Charles Balch教授接受本刊采访,针对“如何在高质量医学杂志发表论文”给出建议,并分享了一些他与CSCO的故事。 
 

 

  Oncology Frontier: Dr. Balch, congratulations for winning the “Honorary foreign consultant award". This year marks the 20th anniversary of CSCO,?will you share some of your stories with CSCO?

  Dr Balch: I have been involved with CSCO as an organization since 2001. Seventeen years ago, the first President, Professor Datong Chu, approached me at an ASCO Meeting with a big vision of this new organization, the Chinese Society of Clinical Oncology. His vision and the vision of the leadership of CSCO was for this organization in China to have the same scale and value as ASCO. This was a big vision, because, at the time, the membership and attendance at the CSCO Meetings was around 1000 people, but their vision was that there would be 20000 or more attendees, even in those early days. The reason they approached me as the CEO of ASCO was because they wanted to know how we were organized, so as CSCO grew, it could absorb the growth and provide good membership service for its new members. That started a partnership between CSCO and ASCO that has gone on through all these years as CSCO and ASCO have grown as organizations and as they have grown closer in their partnership with joint projects. We were supposed to have our first meeting at the CSCO Meeting in September 2001. I had my tickets and was ready to go, and the terrorist attack of 9/11 occurred and all flights were canceled. Datong Chu sent me an email saying “I hate those terrorists” because it prevented us all meeting in 2001. We did, however, all come in 2002 for the meeting in Guangzhou. There was Dr Paul Bunn, the President, Dr Margaret Tempero, the new Director of International Affairs, Paula Rieger, and myself, and we met with Drs Chu, Sun and a young person named Yilong Wu, who eventually became President. After that, we started programs, such as a multidisciplinary cancer management course, which we held in Xian and other cities. There was the Best of ASCO, for which the Best of ASCO in China is the best attended of any ASCO session anywhere in the world. The partnership has been meaningful over the years with joint symposia almost each year that take into account our collaboration as partners on the world stage. Here we are at the 20th Anniversary where the original vision of the leaders of CSCO has been realized with attendance >20000, with a meeting that is one of the best on the world stage, and an organizational structure and exhibit hall and themes that are very much like an ASCO Meeting, because we grew up together as partners. I feel good about watching the growth of CSCO as an organization, but I also have a great deal of respect for those early leaders of CSCO in the first five years, when they originally had the vision to be a first-tier oncology organization for all of China, to exist on a large scale and to have a role in transmitting research and education to all physicians who treat cancer, not only in China, but throughout the world. Another part of what we did together was to start an English-language oncology journal, which became Chinese Clinical Oncology. Dr Dan Haller, who is the Editor-in-Chief of the Journal of Clinical Oncology and myself as Editor-in-Chief of the Annals of Surgical Oncology, both helped in those early years to form Chinese Clinical Oncology. We became the Associate Editors, and then last year, I became the Co-Editor-in-Chief of Chinese Clinical Oncology, which is endorsed by CSCO as one of its educational journals and an English-language journal allowing China and other countries to share our thoughts and procedures and how we treat cancer patients, how we organize our research, and how we can become partners together.

  Oncology Frontier: You have a lecture at the President Symposium?on how to?write the result of research,?would you please introduce the main points of your presentation?

  Dr Balch: I commend Dr Yilong Wu for introducing in his last presidential year a Presidential Symposium related to research. The strategy is for Chinese researchers, both laboratory and clinical, to not only influence science and clinical care in China, but also to influence cancer care and research around the world. He organized a very nice symposium, which essentially said that the rules that we follow around the world are: to have prospective, clean data; to do clinical trials to validate new therapies; and then to communicate that new knowledge through English-language journals. I was privileged to be on the podium with Professor David Collingridge, the Editor-in-Chief of Lancet Oncology, which represents one of the world-class oncology journals. I was representing Chinese Clinical Oncology and the Annals of Surgical Oncology. Both of us had more-or-less the same message – to publish in high quality medical journals, the research has to be organized around a hypothesis that tells a story, that is original and significant, and that is published in fluent and smooth English. One of my and Professor Collingridge’s points as well is that if Chinese investigators want to influence research and patient care in China, they can publish in China and achieve that. But they have the possibility of impacting on and adding value to research and patient care throughout the word. In that case, they need to publish in English-language journals, because English is the scientific language of the world today, both in laboratory research and clinical research. As the common language, if we are going to learn from our Chinese collaborators, then they have learned that it has to be published in a high quality English-language medical or scientific journal. That was our message.

  Oncology Frontier: As the editor-in-chief?of?Annals of Surgical Oncology, could you give Chinese researchers some advice on publishing research papers?

  Dr Balch: I am here in China representing the Annals of Surgical Oncology because Chinese investigators and Chinese surgeons are one of our main clients. We receive more manuscripts from China to our journal than any other country outside of America, so it is very important that we have a good client relationship. It is an opportunity to tell Chinese researchers and clinical investigators how to compete to get their manuscript published in our journal. It comes down to: originality; significance; and framing the story around a hypothesis. I have found that in reading manuscripts that we end up rejecting, the authors have a very diffuse story that is more about look at all the patients I have treated or all the research I have done, but as a reader, I want to know what you have learned from that experience, so that I can now understand and incorporate it into my knowledge pool. A journal is the medium for transmitting that new knowledge. We are looking for well-told stories around a solid hypothesis with good data to back it up, and a discussion that puts the research in a context with the rest of the published literature. What I find is that there are many manuscripts from China and other countries where English is not the native language, where there is a nucleus of good science and information, but the story is not told well around a hypothesis or a focused theme, or the paper is not written in good English. Therefore, even though the science is good, we may end up rejecting the manuscript because it is not written in fluent smooth English. My message for the audience here in China is to be sure you tell a solid story around a hypothesis with good science and methodology, but equally important is to tell your story in smooth and fluent English. Many Chinese are not fluent in English scientifically. They may be good in conversational English, but not necessarily writing scientific English. So one of our recommendations is to use editorial services. Even more than that, I would spend the money using editorial services that are based in English-speaking countries such as England, the United States or Canada, so that the people who are helping in an editorial role understand the nuances of the English language so that the translation from Mandarin to English is smooth and accurate, and tells a compelling, interesting story.

 
  《肿瘤瞭望》:恭喜您获得CSCO荣誉外籍顾问奖,能不能与我们分享一些您和CSCO的故事?
 
  Balch教授:我从2001年起参与CSCO的相关事宜。在17年前,第一任CSCO执行委员会主任委员储大同在ASCO会议上首次与我接触。他和我分享了一个全新组织的蓝图:中国临床肿瘤学会(CSCO)。他和CSCO领导人的愿景是:希望CSCO能够在规模和重要性上都和ASCO相当。这是一个非常高的期待,因为当时CSCO会员和年会出席人数约为1000人,但那时他们的设想已然是能有逾2万的参会人员。因为我是ASCO的首席执行官,他们接触我的理由是想知道我们是如何将ASCO组织起来的,CSCO如何更好地增长和壮大,并为新成员提供良好的会员服务。这就是CSCO和ASCO伙伴关系的开启。
 
  这些年来,CSCO和ASCO都各自成长为规模很大的组织,它们的关系也在联合项目的合作中越来越紧密。我们本应在2001年9月的CSCO会议上开始我们的第一次会晤。在我已经买好机票准备出发的时候,911恐怖袭击发生了并且所有的航班都被取消了。储大同给我发了一封电子邮件,他在邮件中说“我讨厌恐怖分子”,因为它阻止了我们在2001年的所有会议。不过,在2002年,我们在广州完成了这次会议。出席这次会议中有Paul Bunn、Margaret Tempero、Paula Rieger和我。在这次会议上我们见到了储医生,孙医生和一个叫吴一龙的年轻人,吴一龙先生最后成为了CSCO理事长。在那之后,我们开始进行一些项目合作,比如我们在西安和其他城市举办的肿瘤多学科管理课程,在中国举行 Best of ASCO会议,BOA会议在中国的参会情况比其他任何地区都好。还有我们几乎每年都举行的联合会议,这是非常有意义的。
 
  现在已经是第20届CSCO年会,CSCO早期领导人的愿景:出席人数>20000已经成功实现了,而且CSCO年会已经成为了世界上最好的会议之一。因为ASCO和CSCO作为合作伙伴共同发展,CSCO的组织结构、会议展厅和主题都和ASCO非常相似。我非常开心看到CSCO的成长,我对CSCO的早期(特别是前5年)的领导人怀有非常敬意。
 
  我们共同创办英文期刊,即《中国临床肿瘤》(Chinese Clinical Oncology)。当时作为Journal of Clinical Oncology主编的Dan Haller博士和作为Annals of Surgical Oncology主编的我,一起帮助创建了这个杂志,我们成为了副编辑,去年我成为了联合主编。该杂志被CSCO认证为它的教育期刊之一。英文杂志可使中国和其他国家分享思想,交流如何治疗癌症患者,如何开展研究,以及如何成为合作伙伴。
 
  《肿瘤瞭望》:作为《外科肿瘤学年鉴》主编,您对中国研究者的论文写作和发表有何建议?
 
  Balch教授:在最后一年任期时,吴一龙理事长将研究的写作发表设为CSCO主席研讨会的主题,对此我非常赞赏。他组织了一场很不错的研讨会,会议提出了目前全世界所遵循的发表论文的原则:研究具有前瞻性,数据干净、用临床试验验证新的治疗方式;然后在英文杂志发表文章与世界交流这些新知识。
 
  我代表《外科肿瘤学年鉴》来参加2017 CSCO会议,因为中国研究者和中国外科医师是我们重要的客户群。我们收到来自于中国的稿件远远多于美国以外的其他国家,因此与中国研究者和建立良好关系对我们非常重要。我被邀请在2017 CSCO主席论坛作报告,这是个告知中国研究者和临床研究员如何成功在我们杂志刊登稿件的好机会。成功刊登稿件的关键要素总结来讲为以下几点:原创性、有意义、围绕假设构建一个完整的故事。
 
  我在阅读那些被我们拒绝的稿件时发现,作者大部分展现的是一个分散的故事,他们关注自己治疗过的病人,主持过的临床试验,却是更多地站在一个读者的位置。我想知道的是你从你这些经历中学到了什么,这样我才能理解并吸收这些知识。杂志是传播新知识的媒介。我们渴望的好文章应该是基于一个坚实的假设,并有完整的数据来支持,它讨论的内容能将其与其他已发表的文献相关联。
 
  然而我发现在来自于中国及其他非英语母语国家的稿件中,尽管有的文章有好的科研核心和有价值的信息,但是存在一些问题,要么是没有围绕假说讲好一个故事,或是文章所用的英语并不纯正。因此,尽管那些试验非常好,我们仍会因为其稿件中不流畅的英语而拒绝刊登。
 
  我对中国学者们的建议和意见是,基于科学方法论围绕假设讲述好故事,而文章用通顺流畅的英语撰写同样重要。许多中国人不擅长科学性英语的应用。他们可能擅长英语的日常应用,但不擅长研究性文章的英语书写。我们的一个建议是应用编辑服务,甚至是英语母语国家的编辑服务,比如英国、美国或者加拿大的编辑服务,他们能区分英语语言中的细微差别,这样从汉语翻译的英语更流利更准确,更能讲述好一个有说服力和有趣的故事。
 
  我非常荣幸和David Collingridge博士一起站在了演讲台上,Collingridge博士是《柳叶刀·肿瘤学》的主编,柳叶刀肿瘤学是世界顶级的肿瘤学杂志之一。我们两个人或多或少有着相似的观点——为了在高质量的医学期刊上发表文章,必须围绕一个假设来讲述故事,研究具有原创性,有意义,并且写作使用的英语流利通畅。我和Collingridge博士的其中一个观点是,如果中国的研究者想要影响中国的研究和患者护理,他们可以在中国杂志上发表论文。但是,如果他们想要增加研究的价值和并且影响世界范围内的科学研究和患者护理,他们需要在英语期刊上发表文章,因为无论是在实验室研究还是在临床研究方面,目前英语是世界通用的科学语言,也方便其他国家地区的同行们从中有所收获。这是我们的观点。
 
  专家简介
 
  Charles M. Balch
 
  美国德克萨斯州MD 安德森癌症中心外科学教授
 
  德克萨斯州休斯顿大学的外科学教授
 
  美国约翰霍普金斯研究所
 
  曾担任ASCO执行副主席兼首席执行官(CEO)
 
  美国外科肿瘤学会(SSO)前任主席
 
  The Annals of Surgical Oncology主

 

版面编辑:赵丽丽  责任编辑:张彩琴

本内容仅供医学专业人士参考


CSCO大家访谈录

分享到: 更多